Annual CFO
$1.88 M
+$66.88 M+102.88%
31 December 2023
Summary:
EyePoint Pharmaceuticals annual cash flow from operations is currently $1.88 million, with the most recent change of +$66.88 million (+102.88%) on 31 December 2023. During the last 3 years, it has risen by +$16.31 million (+112.99%). EYPT annual CFO is now -81.79% below its all-time high of $10.30 million, reached on 30 June 2015.EYPT Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$39.03 M
-$18.85 M-93.42%
30 September 2024
Summary:
EyePoint Pharmaceuticals quarterly cash flow from operations is currently -$39.03 million, with the most recent change of -$18.85 million (-93.42%) on 30 September 2024. Over the past year, it has dropped by -$23.82 million (-156.70%). EYPT quarterly CFO is now -168.44% below its all-time high of $57.02 million, reached on 30 June 2023.EYPT Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$113.49 M
-$23.82 M-26.57%
30 September 2024
Summary:
EyePoint Pharmaceuticals TTM cash flow from operations is currently -$113.49 million, with the most recent change of -$23.82 million (-26.57%) on 30 September 2024. Over the past year, it has dropped by -$125.88 million (-1015.51%). EYPT TTM CFO is now -884.61% below its all-time high of $14.46 million, reached on 30 June 2023.EYPT TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EYPT Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +102.9% | -156.7% | -1015.5% |
| 3 y3 years | +113.0% | -401.2% | -312.2% |
| 5 y5 years | +108.3% | -164.2% | -151.0% |
EYPT Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +102.9% | -168.4% | at low | -884.6% | at low |
| 5 y | 5 years | at high | +102.9% | -168.4% | at low | -884.6% | at low |
| alltime | all time | -81.8% | +102.9% | -168.4% | at low | -884.6% | at low |
EyePoint Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$39.03 M(+93.4%) | -$113.49 M(+26.6%) |
| June 2024 | - | -$20.18 M(-35.3%) | -$89.66 M(+619.5%) |
| Mar 2024 | - | -$31.17 M(+34.9%) | -$12.46 M(-764.6%) |
| Dec 2023 | $1.88 M(-102.9%) | -$23.11 M(+52.0%) | $1.88 M(-84.9%) |
| Sept 2023 | - | -$15.20 M(-126.7%) | $12.40 M(-14.3%) |
| June 2023 | - | $57.02 M(-438.7%) | $14.46 M(-123.4%) |
| Mar 2023 | - | -$16.84 M(+33.7%) | -$61.68 M(-5.1%) |
| Dec 2022 | -$65.00 M(+29.8%) | -$12.59 M(-4.2%) | -$65.00 M(-5.9%) |
| Sept 2022 | - | -$13.14 M(-31.3%) | -$69.08 M(+8.4%) |
| June 2022 | - | -$19.12 M(-5.1%) | -$63.74 M(+15.6%) |
| Mar 2022 | - | -$20.16 M(+20.9%) | -$55.16 M(+10.1%) |
| Dec 2021 | -$50.10 M(+247.1%) | -$16.67 M(+114.0%) | -$50.10 M(+81.9%) |
| Sept 2021 | - | -$7.79 M(-26.1%) | -$27.53 M(+47.9%) |
| June 2021 | - | -$10.54 M(-30.2%) | -$18.61 M(+41.1%) |
| Mar 2021 | - | -$15.10 M(-356.1%) | -$13.19 M(-8.6%) |
| Dec 2020 | -$14.44 M(-74.5%) | $5.89 M(+418.9%) | -$14.44 M(-54.6%) |
| Sept 2020 | - | $1.14 M(-122.2%) | -$31.82 M(-33.3%) |
| June 2020 | - | -$5.12 M(-68.7%) | -$47.72 M(-20.1%) |
| Mar 2020 | - | -$16.34 M(+42.3%) | -$59.71 M(+5.3%) |
| Dec 2019 | -$56.70 M(+151.0%) | -$11.49 M(-22.2%) | -$56.70 M(+25.4%) |
| Sept 2019 | - | -$14.77 M(-13.6%) | -$45.21 M(+7.1%) |
| June 2019 | - | -$17.11 M(+28.3%) | -$42.21 M(+35.4%) |
| Mar 2019 | - | -$13.33 M(+13.3%) | -$31.18 M(+12.5%) |
| Dec 2018 | -$22.59 M(+3.1%) | - | - |
| Sept 2018 | - | -$11.77 M(+93.5%) | -$27.70 M(+26.5%) |
| June 2018 | -$21.91 M(+6.9%) | -$6.08 M(+26.2%) | -$21.91 M(+8.0%) |
| Mar 2018 | - | -$4.82 M(-4.3%) | -$20.28 M(+1.4%) |
| Dec 2017 | - | -$5.04 M(-15.6%) | -$20.00 M(+0.1%) |
| Sept 2017 | - | -$5.97 M(+34.1%) | -$19.97 M(-2.5%) |
| June 2017 | -$20.49 M(+25.6%) | -$4.45 M(-2.0%) | -$20.49 M(+0.5%) |
| Mar 2017 | - | -$4.54 M(-9.3%) | -$20.39 M(+1.2%) |
| Dec 2016 | - | -$5.01 M(-22.8%) | -$20.14 M(+10.0%) |
| Sept 2016 | - | -$6.49 M(+49.2%) | -$18.31 M(+12.2%) |
| June 2016 | -$16.32 M(-258.5%) | -$4.35 M(+1.0%) | -$16.32 M(+9.0%) |
| Mar 2016 | - | -$4.30 M(+35.5%) | -$14.97 M(+2.4%) |
| Dec 2015 | - | -$3.17 M(-29.4%) | -$14.63 M(-249.3%) |
| Sept 2015 | - | -$4.49 M(+49.5%) | $9.80 M(-4.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2015 | $10.30 M(-196.5%) | -$3.01 M(-24.0%) | $10.30 M(-2.1%) |
| Mar 2015 | - | -$3.95 M(-118.6%) | $10.52 M(-16.7%) |
| Dec 2014 | - | $21.25 M(-632.1%) | $12.62 M(-215.9%) |
| Sept 2014 | - | -$3.99 M(+43.4%) | -$10.89 M(+2.0%) |
| June 2014 | -$10.67 M(+22.0%) | -$2.79 M(+50.4%) | -$10.67 M(-5.3%) |
| Mar 2014 | - | -$1.85 M(-17.9%) | -$11.27 M(-1.0%) |
| Dec 2013 | - | -$2.26 M(-40.2%) | -$11.38 M(+4.4%) |
| Sept 2013 | - | -$3.78 M(+11.7%) | -$10.90 M(+24.7%) |
| June 2013 | -$8.74 M(-2.8%) | -$3.38 M(+72.3%) | -$8.74 M(+21.4%) |
| Mar 2013 | - | -$1.96 M(+10.1%) | -$7.20 M(-2.5%) |
| Dec 2012 | - | -$1.78 M(+9.9%) | -$7.38 M(-7.3%) |
| Sept 2012 | - | -$1.62 M(-11.8%) | -$7.96 M(-11.5%) |
| June 2012 | -$9.00 M(+183.9%) | -$1.84 M(-14.2%) | -$9.00 M(+52.1%) |
| Mar 2012 | - | -$2.14 M(-9.2%) | -$5.92 M(+9.8%) |
| Dec 2011 | - | -$2.36 M(-11.3%) | -$5.39 M(+49.2%) |
| Sept 2011 | - | -$2.66 M(-313.7%) | -$3.61 M(+13.9%) |
| June 2011 | -$3.17 M(-132.0%) | $1.25 M(-177.2%) | -$3.17 M(-134.5%) |
| Mar 2011 | - | -$1.61 M(+176.7%) | $9.19 M(-1.6%) |
| Dec 2010 | - | -$583.00 K(-73.7%) | $9.35 M(+8.6%) |
| Sept 2010 | - | -$2.22 M(-116.3%) | $8.61 M(-13.1%) |
| June 2010 | $9.90 M(-217.3%) | $13.61 M(-1031.4%) | $9.90 M(-304.1%) |
| Mar 2010 | - | -$1.46 M(+10.4%) | -$4.85 M(-7.5%) |
| Dec 2009 | - | -$1.32 M(+43.0%) | -$5.24 M(+7.5%) |
| Sept 2009 | - | -$925.00 K(-18.9%) | -$4.88 M(-42.2%) |
| June 2009 | -$8.44 M(+64.0%) | -$1.14 M(-38.5%) | -$8.44 M(-13.4%) |
| Mar 2009 | - | -$1.85 M(+93.6%) | -$9.74 M(-1755.8%) |
| Dec 2008 | - | -$957.00 K(-78.7%) | $588.00 K(-111.0%) |
| Sept 2008 | - | -$4.49 M(+83.9%) | -$5.37 M(+4.3%) |
| June 2008 | -$5.14 M(-75.8%) | -$2.44 M(-128.8%) | -$5.14 M(+90.3%) |
| Mar 2008 | - | $8.47 M(-222.6%) | -$2.70 M(-75.8%) |
| Dec 2007 | - | -$6.91 M(+62.1%) | -$11.17 M(+162.1%) |
| Sept 2007 | - | -$4.26 M | -$4.26 M |
| June 2007 | -$21.21 M(+31.5%) | - | - |
| June 2006 | -$16.14 M(+72.7%) | - | - |
| June 2005 | -$9.34 M(+71.9%) | - | - |
| June 2004 | -$5.44 M(+77.6%) | - | - |
| June 2003 | -$3.06 M(+682.8%) | - | - |
| June 2001 | -$390.90 K | - | - |
FAQ
- What is EyePoint Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals annual CFO year-on-year change?
- What is EyePoint Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals quarterly CFO year-on-year change?
- What is EyePoint Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals TTM CFO year-on-year change?
What is EyePoint Pharmaceuticals annual cash flow from operations?
The current annual CFO of EYPT is $1.88 M
What is the all time high annual CFO for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high annual cash flow from operations is $10.30 M
What is EyePoint Pharmaceuticals annual CFO year-on-year change?
Over the past year, EYPT annual cash flow from operations has changed by +$66.88 M (+102.88%)
What is EyePoint Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of EYPT is -$39.03 M
What is the all time high quarterly CFO for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high quarterly cash flow from operations is $57.02 M
What is EyePoint Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, EYPT quarterly cash flow from operations has changed by -$23.82 M (-156.70%)
What is EyePoint Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of EYPT is -$113.49 M
What is the all time high TTM CFO for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high TTM cash flow from operations is $14.46 M
What is EyePoint Pharmaceuticals TTM CFO year-on-year change?
Over the past year, EYPT TTM cash flow from operations has changed by -$125.88 M (-1015.51%)